Calidi Biotherapeutics Closes $3.9 Million Offering
Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI), a prominent clinical-stage biotechnology firm known for its innovative immunotherapies, recently announced the completion of a significant financial maneuver. The company has entered into an agreement with a single institutional investor to sell 3.3 million shares of its common stock at a price of $0.65 per share. Additionally, the investor has the option of acquiring pre-funded warrants, allowing them to purchase 2.7 million shares at a slightly higher price of $0.649.
The Role of Ladenburg Thalmann
Ladenburg Thalmann & Co. Inc. is tasked with acting as the exclusive placement agent for this offering. Their expertise is crucial in facilitating this type of transaction, ensuring that everything proceeds smoothly and in compliance with regulatory requirements.
Understanding the Concurrent Private Placement
Alongside the registered direct offering, Calidi is engaging in a concurrent private placement that includes issuing series G warrants to the investors. These warrants will enable the purchase of an additional 6.05 million shares of common stock at an exercise price of $0.6954 per share. Importantly, these warrants can only be exercised six months post-issuance and will remain valid for seven and a half years. This structure is designed to provide investors with favorable terms.
Proceeds Allocation
Gross proceeds from both the registered direct offering and private placement are anticipated to reach approximately $3.9 million. Calidi has stated that these funds will predominantly be utilized for working capital and to advance its pre-clinical and clinical initiatives. This funding will play a vital role in propelling the company forward in its quest to develop unique therapies for cancer treatment.
Regulatory Framework for the Offerings
The securities involved in this transaction, excluding the series G warrants, are being offered under a shelf registration statement that has received SEC approval. Calidi’s transparent approach to this offering includes a commitment to filing a prospectus supplement. Investors can expect this documentation to clarify the terms of the offering meticulously.
Details on the Series G Warrants
The series G warrants are structured so as to remain non-registered under applicable federal and state securities laws. This stipulation means that these warrants, alongside the underlying common stock, cannot be immediately sold in the United States unless they comply with any available registration exemptions. This detail is crucial for investors to understand the nature of their investment in Calidi.
About Calidi Biotherapeutics
Calidi Biotherapeutics stands out in the biotechnology industry as a company committed to developing cutting-edge immuno-oncology solutions. With a focus on utilizing potent allogeneic stem cells, which can effectively carry oncolytic viruses, Calidi aims to transform cancer treatment. Their unique technology platforms are particularly beneficial for targeting high-grade gliomas and solid tumors.
Advancements and Future Potential
The biotherapeutics developed by Calidi are not only designed to amplify the immune response against tumors but are also tailored for patient safety. Their innovative approach demonstrates a clear commitment to enhancing treatment efficacy while minimizing potential side effects. As Calidi continues to advance its clinical programs, it strives to position itself at the forefront of the oncology treatment landscape.
Frequently Asked Questions
What is the total amount raised from the offerings?
The total amount raised from the registered direct offering and concurrent private placement is expected to be approximately $3.9 million.
Why are the series G warrants significant?
The series G warrants allow investors to purchase additional shares at a fixed price over an extended period, providing them with the potential for financial gains if Calidi's market position strengthens.
How will Calidi utilize the raised funds?
The funds will primarily support working capital and assist in advancing Calidi's pre-clinical and clinical programs related to cancer treatments.
Who is the placement agent for this offering?
Ladenburg Thalmann & Co. Inc. serves as the exclusive placement agent, ensuring the offering adheres to regulatory standards.
What unique technologies does Calidi Biotherapeutics hold?
Calidi utilizes proprietary stem cell-based platforms aimed at enhancing therapies for cancer, focusing on both efficacy and patient safety.
